Pipeline

Therabene’s pipeline runs from Discovery to Approval. We are advancing TB-008, a CDK9 degrader, as the lead program with IND-enabling work planned. TB-003B, another CDK9 degrader, is our backup molecule. TB-M002 (c-Myc inhibitor) and TB-010 (CDK9 inhibitor) are in early preclinical stage.